PL2179035T3 - Zmodyfikowany bakteriofag zawierający gen małego rozpuszczalnego w kwasach białka zarodnikowego alfa/beta (SASP) - Google Patents

Zmodyfikowany bakteriofag zawierający gen małego rozpuszczalnego w kwasach białka zarodnikowego alfa/beta (SASP)

Info

Publication number
PL2179035T3
PL2179035T3 PL08786965T PL08786965T PL2179035T3 PL 2179035 T3 PL2179035 T3 PL 2179035T3 PL 08786965 T PL08786965 T PL 08786965T PL 08786965 T PL08786965 T PL 08786965T PL 2179035 T3 PL2179035 T3 PL 2179035T3
Authority
PL
Poland
Prior art keywords
sasp
gene
alpha
modified bacteriophage
small acid
Prior art date
Application number
PL08786965T
Other languages
English (en)
Inventor
Heather Fairhead
Adam Wilkinson
Sarah Holme
Katy Pitts
Alison Jackson
Original Assignee
Phico Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phico Therapeutics Ltd filed Critical Phico Therapeutics Ltd
Publication of PL2179035T3 publication Critical patent/PL2179035T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
PL08786965T 2007-08-07 2008-08-06 Zmodyfikowany bakteriofag zawierający gen małego rozpuszczalnego w kwasach białka zarodnikowego alfa/beta (SASP) PL2179035T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0715416.4A GB0715416D0 (en) 2007-08-07 2007-08-07 Modified bacteriophage
EP08786965A EP2179035B8 (en) 2007-08-07 2008-08-06 Modified bacteriophage including an alpha/beta small acid-soluble spore protein (sasp) gene
PCT/EP2008/060360 WO2009019293A1 (en) 2007-08-07 2008-08-06 Modified bacteriophage including an alpha/beta small acid-soluble spore protein (sasp) gene

Publications (1)

Publication Number Publication Date
PL2179035T3 true PL2179035T3 (pl) 2013-08-30

Family

ID=38543208

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08786965T PL2179035T3 (pl) 2007-08-07 2008-08-06 Zmodyfikowany bakteriofag zawierający gen małego rozpuszczalnego w kwasach białka zarodnikowego alfa/beta (SASP)

Country Status (13)

Country Link
US (4) US8697049B2 (pl)
EP (1) EP2179035B8 (pl)
JP (3) JP5582354B2 (pl)
AU (1) AU2008285659B2 (pl)
CA (1) CA2695939C (pl)
DK (1) DK2179035T3 (pl)
ES (1) ES2402176T3 (pl)
GB (2) GB0715416D0 (pl)
HR (1) HRP20130250T1 (pl)
PL (1) PL2179035T3 (pl)
PT (1) PT2179035E (pl)
SI (1) SI2179035T1 (pl)
WO (1) WO2009019293A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715416D0 (en) * 2007-08-07 2007-09-19 Phico Therapeutics Ltd Modified bacteriophage
GB201417805D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifield bacteriophage
GB201417810D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
GB201417808D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modified bacteriophage
GB201417811D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
CN113215115B (zh) 2014-12-16 2024-07-02 C3J治疗公司 用于体外病毒基因组工程的组合物和方法
GB2544956A (en) * 2015-07-08 2017-06-07 Phico Therapeutics Ltd Polypeptides, polynucleotides and uses thereof
GB201600075D0 (en) * 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
US10736928B2 (en) 2016-01-20 2020-08-11 Richard Brian Murphy, JR. Pegylated recombinant bacteriophage
CA3020371A1 (en) * 2016-04-08 2017-10-12 Phico Therapeutics Ltd. Modifying bacteriophage
CA3020375A1 (en) 2016-04-08 2017-10-12 Phico Therapeutics Ltd Modified bacteriophage
AU2019208460A1 (en) * 2018-01-19 2020-09-03 Cytophage Technologies Inc. Genetically engineered bacteriophage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028130D0 (en) * 2000-11-17 2001-01-03 Phico Therapeutics Ltd Polypeptide and uses thereof
GB0314469D0 (en) * 2003-06-20 2003-07-23 Phico Therapeutics Ltd Antimicrobial compositions and uses thereof
DE102004061846A1 (de) * 2004-12-22 2006-07-13 Basf Ag Mehrfachpromotoren
AU2006287306A1 (en) * 2005-09-09 2007-03-15 Duke University Tissue engineering methods and compositions
GB0715416D0 (en) 2007-08-07 2007-09-19 Phico Therapeutics Ltd Modified bacteriophage

Also Published As

Publication number Publication date
DK2179035T3 (da) 2013-04-08
JP2014221038A (ja) 2014-11-27
JP2010535482A (ja) 2010-11-25
PT2179035E (pt) 2013-04-04
WO2009019293A1 (en) 2009-02-12
US20140242032A1 (en) 2014-08-28
US9359596B2 (en) 2016-06-07
ES2402176T3 (es) 2013-04-29
AU2008285659A1 (en) 2009-02-12
GB0814385D0 (en) 2008-09-10
US11559560B2 (en) 2023-01-24
US20100239536A1 (en) 2010-09-23
HRP20130250T1 (hr) 2013-04-30
CA2695939C (en) 2013-11-19
US20190071648A1 (en) 2019-03-07
EP2179035B1 (en) 2013-02-27
JP2016144444A (ja) 2016-08-12
JP6177357B2 (ja) 2017-08-09
GB2451750A (en) 2009-02-11
SI2179035T1 (sl) 2013-05-31
AU2008285659B2 (en) 2013-09-19
US8697049B2 (en) 2014-04-15
GB0715416D0 (en) 2007-09-19
JP5582354B2 (ja) 2014-09-03
GB2451750B (en) 2010-06-02
US20160319244A1 (en) 2016-11-03
US10106784B2 (en) 2018-10-23
EP2179035A1 (en) 2010-04-28
EP2179035B8 (en) 2013-04-03
CA2695939A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
SI2179035T1 (sl) Modificiran bakteriofag, ki vključuje gen alfa/beta majhnega, v kislini topnega sporinega proteina (SASP)
HUE041429T2 (hu) Vas-oxi-hidroxidot tartalmazó gyógyászati készítmények
HUS1900046I1 (hu) Triazinonokat és vasat tartalmazó készítmények
IL205705A (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
ZA201009074B (en) Axmi-115,axmi-113,axmi-005,axmi-163 and axmi-184:vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
BRPI0818311A2 (pt) manipulador médico
ZA200906699B (en) Insecticidal proteins
SI2592148T1 (sl) Izražanje beljakovin iz več nukleinskih kislin
BRPI1014998A2 (pt) peptídio auxiliador de antígeno de câncer
EP2283131A4 (en) HIGHLY PLASMID DNA PREPARATIONS AND METHOD FOR THE PRODUCTION THEREOF
EP2071025A4 (en) PRIMER SET FOR THE REINFORCEMENT OF THE UGT1A1 GENE, REAGENT FOR THE REINFORCEMENT OF THE UGT1A1 GENE THEREFOR AND APPLICATION THEREOF
HUE047767T2 (hu) Macitentánt tartalmazó terápiás készítmények
EP2358907A4 (en) AUTISM ASSOCIATED GENETIC MARKERS
EP2212435A4 (en) FUSIONED GENE BZW. FUSIONED GENES
PL2086576T3 (pl) Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne
EP2011880A4 (en) Taurine-GEN
DK1978981T3 (da) Præparater til vaginal anvendelse
DE602007001713D1 (de) Medizinische Röhrenanordnung
EP1835927A4 (en) MODIFIED BETATHYMOSINE PEPTIDES
DE602006016764D1 (de) Medizinisches Telemetriesystem
EP2055775A4 (en) PRIMER ASSEMBLY FOR AMPLIFYING THE CYP2C9 GENE, A REAGENT FOR CYP2C9 GENE AMPLIFICATION, AND USE THEREOF
BRPI0917518A2 (pt) formulações de canfosfamida e suas preparações
EP2009981A4 (en) ARRANGEMENT FOR HANDLING LAWN CUT
HRP20150021T1 (xx) Spojevi fenantrenona, pripravci i postupci
ZA200902023B (en) Novel H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use